Home / Journals / OR / Vol.30, No.1, 2022
Special lssues
  • Open AccessOpen Access

    REVIEW

    Is autophagy induction by PARP inhibitors a target for therapeutic benefit?

    AHMED M. ELSHAZLY1,2, TUONG VI V. NGUYEN1, DAVID A. GEWIRTZ1,*
    Oncology Research, Vol.30, No.1, pp. 1-12, 2022, DOI:10.32604/or.2022.026459
    Abstract PARP inhibitors have proven to be effective in conjunction with conventional therapeutics in the treatment of various solid as well as hematologic malignancies, particularly when the tumors are deficient in DNA repair pathways. However, as the case with other chemotherapeutic agents, their effectiveness is often compromised by the development of resistance. PARP inhibitors have consistently been reported to promote autophagy, a process that maintains cellular homeostasis and acts as an energy source by the degradation and reutilization of damaged subcellular organelles and proteins. Autophagy can exhibit different functional properties, the most prominent being cytoprotective. In addition, both cytotoxic and non-protective… More >

  • Open AccessOpen Access

    ARTICLE

    Comprehensive analysis of the expression and prognosis for APOE in malignancies: A pan-cancer analysis

    SHOUKAI YU1,2,3,*, LINGMEI QIAN1, JUN MA1,*
    Oncology Research, Vol.30, No.1, pp. 13-22, 2022, DOI:10.32604/or.2022.026141
    Abstract Apolipoprotein E (APOE), a gene identified as one of the strongest genetic factors contributing to the risk determinant of developing late-onset Alzheimer’s disease (AD), may also contribute to the risk of cancer. However, no pan-cancer analysis has been conducted specifically for the APOE gene. In this study, we investigated the oncogenic role of the APOE gene across cancers by GEO (Gene Expression Omnibus) and TCGA (The Cancer Genome Atlas). Based on the available data, we found that most cancer types overexpress APOE, and clear associations exist between the expression level of APOE and prognosis in tumor patients. The expression of… More >

  • Open AccessOpen Access

    ARTICLE

    Transarterial chemoembolization vs. liver resection as initial treatment for hepatocellular carcinoma occurring exclusively in caudate lobe: A retrospective propensity matching analysis

    BIAO YANG1,3,#,*, MINLAN YUAN2,#, TING YANG1,#, ZHENGYIN LIAO1, HAO WU3,*
    Oncology Research, Vol.30, No.1, pp. 23-33, 2022, DOI:10.32604/or.2022.026044
    Abstract Treatment of hepatocellular carcinoma (HCC) in the caudate lobe is technically challenging. This retrospective study was designed to evaluate the clinical outcome of both superselective transcatheter arterial chemoembolization (TACE) and liver resection (LR) for HCC occurring exclusively in the caudate lobe. From January 2008 to September 2021, a total of 129 patients were diagnosed with HCC of the caudate lobe. The Cox proportional hazard model was used to analyze the potential clinical factors and established prognostic nomograms with interval validation. Of the total number of patients, 78 received TACE and 51 received LR. The overall survival (OS) rates (TACE vs.… More >

  • Open AccessOpen Access

    ARTICLE

    Integrative multiomics analysis identifies a metastasis-related gene signature and the potential oncogenic role of EZR in breast cancer

    GUODONG XIAO1,#, FENG CHENG1,#, JING YUAN1, WEIPING LU1, PEILI WANG2, HUIJIE FAN1,*
    Oncology Research, Vol.30, No.1, pp. 35-51, 2022, DOI:10.32604/or.2022.026616
    Abstract Distant metastasis is a major cause of increased mortality in breast cancer patients, but the mechanisms underlying breast cancer metastasis remain poorly understood. In this study, we aimed to identify a metastasis-related gene (MRG) signature for predicting progression in breast cancer. By screening using three regression analysis methods, a 9-gene signature (NOTCH1, PTP4A3, MMP13, MACC1, EZR, NEDD9, PIK3CA, F2RL1 and CCR7) was constructed based on an MRG set in the BRCA cohort from TCGA. This signature exhibited strong robustness, and its generalizability was verified in the Metabric and GEO cohorts. Of the nine MRGs, EZR is an oncogenic gene with… More >

Per Page:

Share Link